{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-002861","form_type":"8-K","ticker":"NGNE","cik":"0001404644","company_name":"Neurogene Inc.","filed_at":"2024-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.074767+00:00","generated_at":"2026-06-07T03:02:20.694616+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Neurogene reports ~$200M cash; DSMB clears third patient in Rett syndrome trial","bullets":["DSMB cleared third pediatric patient for dosing in NGN-401 Phase 1/2 for Rett syndrome; dosing expected early Q1 2024.","UK MHRA approved CTA for NGN-401, enabling trial expansion beyond US.","Ended 2023 with ~$200M cash; cash runway into 2H 2026.","Plan to report interim Phase 1/2 data for NGN-401 in 4Q 2024 and NGN-101 in 2H 2024; FDA discussions for NGN-101 in 2H 2024.","Extended research collaboration with University of Edinburgh by three years; plan to advance one discovery product into clinic in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-002861","json":"https://secwatch.observer/filing/0001193125-24-002861.json","markdown":"https://secwatch.observer/filing/0001193125-24-002861.md","text":"https://secwatch.observer/filing/0001193125-24-002861.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1404644/000119312524002861/0001193125-24-002861-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1404644/000119312524002861/d828702d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T03:02:20.694616+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}